Statement:  Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.
Primary_evidence: INTERVENTION 1:    Treatment (Pazopanib Hydrochloride)   Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.   pazopanib hydrochloride: Given orally   pharmacological study: Correlative studies   laboratory biomarker analysis: Correlative studies